Von der effektiven Dosis in der Diagnostik zur patienten - spezifischen Dosimetrie in der nuklearmedizinischen Therapie

 

^* Zitat aus: Krieger (14), Kapitel 7 Eintrag Nuklearmedizin „Aufgaben und Genauigkeit der klinischen Dosimetrie“.

• Literatur

• 1 Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962; 87: 171-182.
• 2 Buckley SE, Chittenden SJ, Saran FH. et al. Wholebody dosimetry for individualized treatment planning of ¹³¹I-MIBG radionuclide therapy for neuro - blastoma. J Nucl Med 2009; 50: 1518-1524.
• 3 Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation. National Research Council, Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2.. Washington, D.C.: The National Academies Press; 2006
• 4 Dewaraja YK, Schipper MJ, Roberson PL. et al. ¹³¹I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med 2010; 51: 1155-1162.
• 5 Eberlein U, Broer JH, Vandevoorde C. et al. Bio - kinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine – a review. Eur J Nucl Med Mol Imaging. 2011
• 6 Flux GD, Haq M, Chittenden SJ. et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010; 37: 270-275.
• 7 Geworski L, Schaefer A, Knoop BO. et al. Physical aspects of scintigraphy-based dosimetry for nuclear medicine therapy. Nuklearmedizin 2010; 49: 85-95.
• 8 Hellwig D, Grgic A, Kotzerke J, Kirsch CM. Nuclear Medicine in Germany. Key data from official statistics. Nuklearmedizin 2011; 50: 53-67.
• 9 ICRP. Publication 53: Radiation Dose to Patients from Radiopharmaceuticals. Ann ICRP. 1987 18. 1–4
• 10 ICRP. Publication 60: 1990 recommendations of the International Commission on Radiological Protection. Ann ICRP. 1991 21. 1–3
• 11 ICRP. Publication 80: Radiation dose to patients from radiopharmaceuticals: Addendum 2 to ICRP publication 53. Ann ICRP. 1998 28. 3
• 12 ICRP. Publication 103: The 2007 recommendations of the International Commission of Radiological Protection. Ann ICRP. 2007 37. 2–4.
• 13 ICRP. Publication 106: Radiation dose to patients from radiopharmaceuticals: Addendum 3 to ICRP Publication 53. Ann ICRP. 2008 38. 1–2.
• 14 Krieger H. Strahlungsmessung und Dosimetrie Wiesbaden: Vieweg + Teubner. 2011
• 15 Lassmann M. Dosimetry of short-ranged radionuclides. Nuklearmedizin 2010; 49 (Suppl) S46-S49.
• 16 Lassmann M, Brans B, Behr T. Introduction 1st International Symposium on Radionuclide Therapy and Radiopharmaceutical Dosimetry. Cancer Biother Radiopharm 2005; 20: 45-46.
• 17 Lassmann M, Chiesa C, Flux G, Bardies M. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging 2011; 38: 192-200.
• 18 Matthay KK, Panina C, Huberty J. et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with ¹³¹I-MIBG. J Nucl Med 2001; 42: 1713-1721.
• 19 Strigari L, Benassi M, Chiesa C. et al. Dosimetry in nuclear medicine therapy: radiobiology application and results. Q J Nucl Med Mol Imaging 2011; 55: 205-221.
• 20 Strigari L, Sciuto R, Rea S. et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med 2010; 51: 1377-1385.
• 21 Verburg FA, Lassmann M, Mader U. et al. The absorbed dose to the blood is a better predictor of ablation success than the administered ¹³¹I activity in thyroid cancer patients. Eur J Nucl Med Mol Imaging 2011; 38: 673-680.